Treatment of Cystoisosporiasis in Patients with Allergy to or Intolerance of Trimethoprim-Sulfamethoxazole

When a patient with Cystoisosporiasis has a documented allergy to or intolerance of trimethoprim-sulfamethoxazole (TMP-SMX), a different treatment approach is required. The protocol below addresses this specific clinical scenario.

Clinical Scenario

Allergy to or intolerance of trimethoprim-sulfamethoxazole (TMP-SMX). Patients who cannot tolerate TMP-SMX due to allergy or intolerance require an alternative treatment pathway for Cystoisosporiasis.

Treatment Approach

In this setting, an alternative antiparasitic agent is used, given together with a supplement to protect against bone marrow suppression. The complete regimen — including agent selection, dosing, frequency, and duration — is detailed in the structured protocol.

Full regimen and schedule available via the protocol below.

Instant Access to Structured Evidence-Based Regimens

References

Patients who are allergic to (or are intolerant of) TMP-SMX usually are treated with pyrimethamine.

For adults, the typical daily dose of pyrimethamine is in the range of 50 to 75 mg.

This daily dose is given orally, either once a day or divided into 2 separate doses.

Pyrimethamine can suppress the bone marrow.

To help prevent this, patients treated with pyrimethamine also take leucovorin, orally, in a daily dose in the range of 10 to 25 mg.

View source ↗